度普利尤单抗降阶策略维持成人和青少年特应性皮炎缓解:一项非劣效随机试验的研究方案(MADULO)
MADULO是一项多中心非劣效随机对照试验,计划纳入256名已接受标注剂量度普利尤单抗治疗至少12个月且病情控制的青少年和成人特应性皮炎患者,1:1随机分为渐进式降阶注射策略组与标准维持治疗组,主要终点为一年内每周记录的湿疹控制工具评分的曲线下面积。
要点
- 多中心非劣效随机对照试验,纳入31家学术医院256名病情控制的青少年和成人特应性皮炎患者。
- 实验组采用渐进式降阶注射策略,对照组为标准维持治疗(300 mg每两周一次,12岁以上青少年按体重调整剂量)。
- 主要终点为一年内每周记录的湿疹控制工具评分的曲线下面积。
核心结论
- 研究假设在病情控制的青少年和成人特应性皮炎患者中间隔度普利尤单抗注射是一种有意义的维持治疗选择。
- 本试验旨在比较降阶策略(间隔度普利尤单抗注射)与标准维持治疗在病情控制患者中的效果。
研究设计与样本
- 多中心非劣效随机对照试验,计划纳入256名青少年和成人特应性皮炎患者。
- 纳入标准为接受标注剂量度普利尤单抗治疗至少12个月且病情控制,来自31家学术医院。
- 参与者按1:1比例随机分配至实验组(渐进式降阶注射策略)或对照组(标准维持治疗,即300 mg每两周一次;12岁以上青少年按体重调整剂量)。
关键数值与推荐
- 主要终点为一年内每周记录的湿疹控制工具评分的曲线下面积。
- 对照组标准维持治疗为300 mg每两周一次;12岁以上青少年剂量根据体重调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atopic dermatitis (AD) is a prevalent chronic relapsing inflammatory skin disease affecting individuals across the lifespan from childhood through adulthood. The burden of AD is now well recognized. Recent advancements in understanding its pathophysiology have led to significant therapeutic improvements over the past five years. Dupilumab stands as one of the pioneering systemic treatments available for AD. While dupilumab enables rapid and substantial short-term disease control, assessing the effectiveness of long-term therapeutic strategies is crucial. Improving knowledge on the management of maintenance treatment is a key clinical question for patients and clinicians. We hypothesize that spacing dupilumab injections in adolescent and adult patients with controlled AD is an interesting maintenance treatment option. This randomized clinical trial aims to compare a step-down strategy involving spaced dupilumab injections with standard maintenance treatment in patients with controlled AD. METHODS: This multicenter non-inferiority randomized controlled trial will enroll 256 adolescents and adults with controlled AD treated with a labelled dose of dupilumab for at least 12 months from thirty-one academic hospitals. Participants will be randomly assigned in a 1:1 ratio to either the experimental group (progressive step-down injection strategy) or the control group (standard maintenance treatment, i.e., 300 mg dose administered every two weeks; for adolescents over the age of 12, the dose is adjusted according to weight). The primary outcome measure will be the Area under the Curve of the Atopic Dermatitis Control Tool score recorded weekly over one year. DISCUSSION: In clinical practice, AD patients who respond favorably to dupilumab often express interest in reducing treatment frequency, sometimes on their own initiative. Anticipated benefits of a step-down strategy include potentially improved long-term risk-benefit profiles and enhanced patient quality of life through reduced injection frequency. Collectively, this approach may yield insights into optimal long-term dupilumab strategies for responders while potentially lowering systemic treatment costs for healthcare providers. TRIAL REGISTRATION: Clinical trial.gov: NCT05642208 first published on 8 December 2022 ( https://clinicaltrials.gov/study/NCT05642208?term=MADULO&rank=1 ); Clinical Trials Information System, EUCT number: 2022-501179-23-00 first published on 8 November 2022 ( https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2022-501179-23-00 ).
引用
- Foureau A, Faurel-Paul E, Hardouin JB, et al. Dupilumab step-down strategy to maintain remission in adult and adolescent patients with atopic dermatitis: study protocol for a non-inferiority randomized trial (MADULO). Trials. 2025. PMID: 41350756. doi:10.1186/s13063-025-09325-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。